The Department of Health (DH) is set to enhance its medical device procurement strategy, building on the first phase implemented on June 21, 2023. The second phase of this strategy will be introduced in two stages to ensure better quality and safety of medical devices used in public healthcare facilities.
Stage 1 (Effective November 1, 2024):
From this date, all DH quotation exercises will mandate that applicable medical devices (AMD) must be listed under the Medical Device Administrative Control System (MDACS) or have a listing application submitted with an assigned Application Number by the closing time of the quotation. Preference will be given to listed medical devices for all quotations and tenders.
Stage 2 (Expected in 2025, post-Stage 1 review):
In this stage, the requirement will be stricter, requiring all AMDs procured by DH to be already listed under MDACS.
This strategy supports the government’s commitment to ensuring the safety, quality, and performance of medical devices in public healthcare. The DH anticipates an increase in listing applications and encourages traders and companies to apply for their AMDs listing under MDACS promptly. Application forms and guidance notes are available on the Medical Device Division (MDD) website.
To be included in the supplier lists of the government, companies can apply for inclusion in DH’s supplier list or inclusion in the supplier list of the Government Logistics Department (GLD). The DH invites companies to join its supplier lists for medical goods and services, free of charge, by submitting a completed application form to its Supplies Section. Accepted firms must demonstrate competitive offers and satisfactory performance to remain listed. The GLD maintains categorized supplier lists for various goods and services, with applications accepted online or via form submission, free of charge. Listed suppliers receive tender notifications when opportunities arise.
Written by: Ames Gross – President and Founder, Pacific Bridge Medical (PBM)
Mr. Gross founded PBM in 1988 and has helped hundreds of medical companies with regulatory and business development issues in Asia. He is recognized nationally and internationally as a leader in the Asian medical markets. Mr. Gross has a BA degree, Phi Beta Kappa, from the University of Pennsylvania and an MBA from Columbia University.